Alaunos Therapeutics annual ebitda
2009
2010
2011
2012
2013
2014
2015
2016
Alaunos Therapeutics EBITDA Growth & History (TCRT)
Alaunos Therapeutics's calculated EBITDA was −$165.0M for fiscal 2016.
View full Alaunos Therapeutics company overviewAlaunos Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2016 | 2016-12-31 | −$165.0M | −$45.3M | — |
| 2015 | 2015-12-31 | −$119.7M | −$76.7M | — |
| 2014 | 2014-12-31 | −$43.0M | $13.9M | — |
| 2013 | 2013-12-31 | −$57.0M | $44.5M | — |
| 2012 | 2012-12-31 | −$101.5M | −$30.4M | — |
| 2011 | 2011-12-31 | −$71.1M | −$46.8M | — |
| 2010 | 2010-12-31 | −$24.4M | −$12.6M | — |
| 2009 | 2009-12-31 | −$11.8M | — | — |
Alaunos Therapeutics quarterly ebitda
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q3 2018 | 2018-09-30 | −$12.4M | $513,000 | — |
| Q2 2018 | 2018-06-30 | −$12.2M | $1.6M | — |
| Q1 2018 | 2018-03-31 | −$16.1M | −$5.0M | — |
| Q3 2017 | 2017-09-30 | −$13.0M | −$2.1M | — |
| Q2 2017 | 2017-06-30 | −$12.9M | $118.2M | — |
| Q1 2017 | 2017-03-31 | −$13.9M | −$1.9M | — |
| Q4 2016 | 2016-12-31 | −$11.0M | −$1.6M | — |
| Q3 2016 | 2016-09-30 | −$10.8M | $7.3M | — |
| Q2 2016 | 2016-06-30 | −$131.2M | −$117.0M | — |
| Q1 2016 | 2016-03-31 | −$12.0M | $66.1M | — |
| Q4 2015 | 2015-12-31 | −$9.4M | $1.1M | — |
| Q3 2015 | 2015-09-30 | −$18.1M | −$6.3M | — |
| Q2 2015 | 2015-06-30 | −$14.1M | −$3.0M | — |
| Q1 2015 | 2015-03-31 | −$78.1M | −$68.4M | — |
| Q4 2014 | 2014-12-31 | −$10.5M | −$3.9M | — |
| Q3 2014 | 2014-09-30 | −$11.8M | −$2.9M | — |
| Q2 2014 | 2014-06-30 | −$11.1M | $7.0M | — |
| Q1 2014 | 2014-03-31 | −$9.7M | $13.7M | — |
| Q4 2013 | 2013-12-31 | −$6.6M | $32.1M | — |
| Q3 2013 | 2013-09-30 | −$8.9M | $12.6M | — |
| Q2 2013 | 2013-06-30 | −$18.1M | $4.7M | — |
| Q1 2013 | 2013-03-31 | −$23.4M | −$4.9M | — |
| Q4 2012 | 2012-12-31 | −$38.7M | −$22.3M | — |
| Q3 2012 | 2012-09-30 | −$21.5M | −$7.4M | — |
| Q2 2012 | 2012-06-30 | −$22.8M | −$10.0M | — |
| Q1 2012 | 2012-03-31 | −$18.5M | $9.4M | — |
| Q4 2011 | 2011-12-31 | −$16.3M | −$7.9M | — |
| Q3 2011 | 2011-09-30 | −$14.1M | — | — |
| Q2 2011 | 2011-06-30 | −$12.8M | — | — |
| Q1 2011 | 2011-03-31 | −$27.9M | — | — |
| Q3 2010 | 2010-09-30 | −$8.5M | — | — |
Alaunos Therapeutics ebitda trends
Over the last five reported fiscal years, Alaunos Therapeutics's ebitda decreased from −$71.1M to −$165.0M, a change of −$93.9M. The latest reported quarter, Q3 2018, shows −$12.4M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alaunos Therapeutics filings at SEC.gov ↗